The Exchange was undertaken pursuant to a Plan of Reorganization that BioCorRx Inc.'s board adopted on February 25, 2026, under which the company intends to acquire full control of BioCorRx Pharmaceuticals within the meaning of Section 368(c) of the Internal Revenue Code. The Exchange itself was structured to qualify as a tax-free reorganization under Section 368(a)(1)(B) of the Code. The company's common stock issued to the shareholders constituted the sole consideration; no cash or other property was paid or transferred. Because the recipients are officers and directors of BioCorRx Inc., the board approved the Exchange under the company's related-party transaction policy, and the agreement grants the shareholders certain registration rights for the shares received, subject to limitations.
No purchase price, enterprise value, or per-share exchange price is disclosed in the filings; the agreement fixed the consideration as a specific share count (2,263,371 shares) rather than a formula tied to a valuation or exchange ratio. BioCorRx Inc.'s first-quarter 2026 Form 10-Q quantifies the accounting impact: the acquisition of the noncontrolling interest was recorded through equity, increasing the noncontrolling interest balance by $158,835 with an offsetting $161,098 adjustment within additional paid-in capital, moving the reported noncontrolling interest deficit from $(303,429) at December 31, 2025 to $(173,259) at March 31, 2026 (a change that also reflects a $28,665 net loss allocation to the noncontrolling interest during the quarter). Because BioCorRx Inc. already controlled and consolidated BioCorRx Pharmaceuticals before the Exchange, the transaction was accounted for as an equity transaction between owners rather than a new business combination; no goodwill or purchase-price allocation is disclosed in connection with it.
The 10-Q states that BioCorRx Inc.'s ownership interest in BioCorRx Pharmaceuticals (and its share of the subsidiary's earnings) increased from 75.8% before March 26, 2026 to 88.15% afterward, with the noncontrolling interest's share of earnings correspondingly reduced from 24.2% to 12.85%. BioCorRx Pharmaceuticals is the operating subsidiary that in 2025 acquired certain assets, including the FDA-approved opioid-withdrawal medication Lucemyra, from USWM, LLC (d/b/a US WorldMeds) under a separate asset purchase agreement; that prior acquisition is unrelated to this stock exchange but provides context on the subsidiary being consolidated.
No financial advisor or legal advisor is identified in any filing related to this transaction; given its nature as an internal, related-party exchange of minority shares for parent stock under a board-adopted reorganization plan, outside advisors may not have been retained, or their involvement was not disclosed.
The Exchange has already closed. BioCorRx Inc.'s Form 8-K filed April 2, 2026 states explicitly that "The Exchange closed on March 27, 2026," and the company's Form 10-Q for the quarter ended March 31, 2026 confirms the share issuance and resulting ownership-percentage shift occurred during that quarter. No pending regulatory approval, shareholder vote, or other closing condition is referenced in any filing; the transaction was a private issuance exempt from registration under Section 4(a)(2) of the Securities Act, based on the restricted, non-public nature of the offer, the direct negotiation between the company and the three accredited-investor shareholders, and the absence of any general solicitation.